“Tralokinumab Demonstrated a Consistent Safety Profile With up to 42 Months of Treatment in Moderate-to-Severe Atopic Dermatitis: Including Adverse Events of Special Interest”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, p. s79, https://doi.org/10.25251/skin.6.supp.79.